MX2023003369A - Formulacion farmaceutica de liberacion prolongada. - Google Patents
Formulacion farmaceutica de liberacion prolongada.Info
- Publication number
- MX2023003369A MX2023003369A MX2023003369A MX2023003369A MX2023003369A MX 2023003369 A MX2023003369 A MX 2023003369A MX 2023003369 A MX2023003369 A MX 2023003369A MX 2023003369 A MX2023003369 A MX 2023003369A MX 2023003369 A MX2023003369 A MX 2023003369A
- Authority
- MX
- Mexico
- Prior art keywords
- extended release
- pharmaceutical formulation
- release pharmaceutical
- treatment
- resistant
- Prior art date
Links
- 238000013265 extended release Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/030,705 US12090123B2 (en) | 2017-10-10 | 2020-09-24 | Extended release pharmaceutical formulation |
| PCT/IB2021/058647 WO2022064387A1 (en) | 2020-09-24 | 2021-09-22 | Extended release pharmaceutical formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003369A true MX2023003369A (es) | 2023-08-14 |
Family
ID=80846364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003369A MX2023003369A (es) | 2020-09-24 | 2021-09-22 | Formulacion farmaceutica de liberacion prolongada. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250049734A1 (https=) |
| EP (1) | EP4216937A4 (https=) |
| JP (1) | JP2023543211A (https=) |
| KR (1) | KR20230074522A (https=) |
| CN (1) | CN116456972A (https=) |
| AU (1) | AU2021350581A1 (https=) |
| CA (1) | CA3190204A1 (https=) |
| MX (1) | MX2023003369A (https=) |
| WO (1) | WO2022064387A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10869838B2 (en) * | 2017-10-10 | 2020-12-22 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| US12090123B2 (en) | 2017-10-10 | 2024-09-17 | Douglas Pharmaceuticals Ltd. | Extended release pharmaceutical formulation |
| WO2024171074A1 (en) * | 2023-02-15 | 2024-08-22 | Clearmind Medicine Inc. | Compositions comprising ketamine, optionally in combination with n-acylethanolamines, and uses thereof |
| WO2025099182A1 (en) * | 2023-11-07 | 2025-05-15 | HMNC Holding GmbH | Induction regime for the administration of 2-(2-chlorphenyl)-2-(methylamino) cyclohexan-1-one |
| WO2025099181A1 (en) * | 2023-11-07 | 2025-05-15 | HMNC Holding GmbH | Maintenance regime for the administration of 2-(2-chlorphenyl)-2-(methylamino) cyclohexan-1-one |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2922507C (en) * | 2013-08-26 | 2022-07-05 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
| DK3215147T3 (da) * | 2014-11-04 | 2024-04-02 | Acadia Pharm Inc | Neurodæmpende norketamin-forbindelser og fremgangsmåder |
| US10441544B2 (en) * | 2017-10-10 | 2019-10-15 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| CN111630026A (zh) * | 2017-10-10 | 2020-09-04 | 道格拉斯制药有限公司 | 缓释药物制剂和治疗方法 |
-
2021
- 2021-09-22 WO PCT/IB2021/058647 patent/WO2022064387A1/en not_active Ceased
- 2021-09-22 CN CN202180072775.8A patent/CN116456972A/zh active Pending
- 2021-09-22 KR KR1020237013515A patent/KR20230074522A/ko active Pending
- 2021-09-22 EP EP21871786.6A patent/EP4216937A4/en active Pending
- 2021-09-22 JP JP2023518735A patent/JP2023543211A/ja active Pending
- 2021-09-22 CA CA3190204A patent/CA3190204A1/en active Pending
- 2021-09-22 MX MX2023003369A patent/MX2023003369A/es unknown
- 2021-09-22 AU AU2021350581A patent/AU2021350581A1/en active Pending
-
2024
- 2024-07-12 US US18/771,903 patent/US20250049734A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4216937A4 (en) | 2024-09-04 |
| WO2022064387A1 (en) | 2022-03-31 |
| CA3190204A1 (en) | 2022-03-31 |
| EP4216937A1 (en) | 2023-08-02 |
| JP2023543211A (ja) | 2023-10-13 |
| KR20230074522A (ko) | 2023-05-30 |
| US20250049734A1 (en) | 2025-02-13 |
| AU2021350581A1 (en) | 2023-03-23 |
| CN116456972A (zh) | 2023-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023003369A (es) | Formulacion farmaceutica de liberacion prolongada. | |
| MX2021009259A (es) | Conjugados de il-2 y metodos de uso del mismo. | |
| CL2019001337A1 (es) | Formulaciones farmacéuticas. | |
| MX2019013171A (es) | Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos. | |
| MX2016006025A (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. | |
| MX2020003546A (es) | Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento. | |
| CO2026004964A2 (es) | Moduladores de kras | |
| CL2012003281A1 (es) | Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica. | |
| MX2019003780A (es) | Uso de la combinación de anticuerpo anti-pd-1 e inhibidor de vegfr en la preparación de medicamentos para el tratamiento de cánceres. | |
| CL2017001001A1 (es) | Derivados de carbazaol | |
| CR20160203A (es) | Inhibidores de tirosina cinasa de bruton | |
| CR20160537A (es) | Inhibidor de fosfoinosítido 3-quinasa delta para su uso medico | |
| DOP2006000050A (es) | Una formulación sólida de dosificación farmaceútica | |
| BR112016029750A2 (pt) | dosagem intermitente de inibidor mdm2 | |
| MX2023001963A (es) | Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino. | |
| UY35455A (es) | Inhibidores tripeptidicos de la epoxicetona proteasa | |
| CR20150563A (es) | Recubrimiento de adhesivo tisular para globos recubiertos de fármacos | |
| MX2019012865A (es) | Anticuerpos anti-interferon gamma y usos de los mismos. | |
| CO6400190A2 (es) | Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma | |
| CL2012001596A1 (es) | Compuestos derivados de triazolopiridina, pirazolopirimidina, triazolopirimidina o pirazolopiridina, modulador alosterico positivo del receptor mglur5; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion de la esquizofrenia o de una enfermedad cognitiva. | |
| CO2020007601A2 (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis | |
| AR070031A1 (es) | Sistemas de administracion transdermicos de droga ketotifen y metodos para el tratamiento de enfermedades oftalmicas | |
| AR112217A1 (es) | Una combinación de un inhibidor de mps1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta | |
| CL2018001157A1 (es) | Formulación de combinación de dosis fija, eflornitina y sulindaco. | |
| WO2020194087A3 (en) | Extended release pharmaceutical formulation |